ELYM ELIEM THERAPEUTICS INC

Climb Bio to Present at Upcoming Investor Conferences

Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below.

Guggenheim Securities Healthcare Innovation Conference

Format: Fireside chat and one-on-one investor meetings

Date: November 11-12, 2024

Stifel 2024 Healthcare Conference

Format: Fireside chat and one-on-one investor meetings

Date: November 18-19, 2024

36th Annual Piper Sandler Healthcare Conference

Format: Fireside chat and one-on-one investor meetings

Date: December 3-5, 2024

7th Annual Evercore ISI HealthCONx Conference

Format: Fireside chat and one-on-one investor meetings

Date: December 3-5, 2024

The presentations will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Climb Bio, Inc.

Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit .

Investors

Chris Brinzey

ICR Healthcare



339-970-2843

Media

Jon Yu

ICR Healthcare



475-395-5375



EN
31/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ELIEM THERAPEUTICS INC

 PRESS RELEASE

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results ...

Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates  Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage ...

Laura Chico ... (+2)
  • Laura Chico
  • Thomas Yip

ResearchPool Subscriptions

Get the most out of your insights

Get in touch